Opinion|Videos|August 23, 2024
Insights from TROPION-Lung05 and HERTHENA-Lung01: Perspectives on the Future Role of ADCs in Advanced EGFR-Mutant NSCLC
Author(s)Martin Dietrich, MD, PhD, Wade Iams, MD
Martin Dietrich, MD, PhD, shares expert perspectives on recent data from TROPION-Lung05 and HERTHENA-Lung01 in advanced EGFR-mutant NSCLC.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly provide your overall thoughts and perspectives on recent data from TROPION-Lung05 and HERTHENA-Lung01.
- What future role do you anticipate for ADCs in advanced EGFR-mutant NSCLC?
- In which patients may you consider ADC-based therapy and how would you choose among potential options?
Advertisement
Related to this article
Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5